Background pattern

Alzerta 9,5 mg/24 h parches transdermicos efg

About the medicine

About the medication

Introduction

Prospecto: Information for the User

Alzerta 4,6 mg/24 h Transdermal Patches EFG

Alzerta 9,5 mg/24 h Transdermal Patches EFG

Rivastigmina

Read this prospectus carefully before starting to use this medication, as it contains important information for you.

  • Keep this prospectus, as you may need to read it again.
  • If you have any doubts, consult your doctor or pharmacist.
  • This medication has been prescribed only to you, and you should not give it to other people even if they have the same symptoms as you, as it may harm them.
  • If you experience any adverse effects, consult your doctor or pharmacist, even if they do not appear in this prospectus.See section 4.

1.What Alzerta is and for what it is used

2.What you need to know before starting to use Alzerta

3.How to use Alzerta

4.Possible adverse effects

5.Storage of Alzerta

6.Contents of the package and additional information

1. What is Alzerta and what is it used for

The active ingredient of Alzerta is rivastigmine.

Rivastigmine belongs to the group of cholinesterase inhibitors. In patients with Alzheimer's disease, certain nerve cells die in the brain, resulting in low levels of the neurotransmitter acetylcholine (a substance that allows nerve cells to communicate with each other). Rivastigmine acts by blocking the enzymes that break down acetylcholine: acetylcholinesterase and butyrylcholinesterase. By blocking these enzymes, rivastigmine allows an increase in acetylcholine in the brain, helping to reduce the symptoms of Alzheimer's disease.

Alzerta is used for the treatment of adult patients with mild to moderately severe Alzheimer's disease, a progressive brain disorder that gradually affects memory, intellectual capacity, and behavior.

2. What you need to know before starting to use Alzerta

Do not use Alzerta

  • If you are allergic to rivastigmine (the active ingredient in Alzerta) or to any of the other components of this medication (listed in section 6).
  • If you have ever had an allergic reaction to a similar medication (carbamate derivatives).
  • If you have a skin reaction that extends beyond the size of the patch, if there is a more intense local reaction (such as blisters, skin inflammation, swelling) and if there is no improvement within 48 hours after removing the transdermal patch.

If you find yourself in any of these situations, inform your doctor and do not use Alzerta transdermal patches.

Warnings and precautions

Consult your doctor before starting to use Alzerta:

  • If you have or have had any heart problems such as irregular or slow heart rhythm, prolonged QTc, family history of prolonged QTc, torsades de pointes, or if you have low blood levels of potassium or magnesium.
  • If you have or have had any active stomach ulcers.
  • If you have or have had any difficulty urinating.
  • If you have or have had any seizures.
  • If you have or have had any severe respiratory disease.
  • If you suffer from tremors.
  • If you have a low body weight.
  • If you have gastrointestinal reactions such as nausea, vomiting, and diarrhea. You may become dehydrated (loss of a large amount of fluid) if vomiting or diarrhea are prolonged.
  • If you have liver problems (hepatic insufficiency).

If you find yourself in any of these situations, your doctor may consider the need for closer monitoring while you are being treated.

If you have not used the patches for more than three days, do not apply another one without consulting your doctor first.

Children and adolescents

There is no experience of the use of this medication in the pediatric population in the treatment of Alzheimer's disease.

Other medications and Alzerta

Inform your doctor or pharmacist if you are taking, have taken recently, or may need to take any other medication.

This medication may interact with anticholinergic medications, some of which are used to relieve stomach cramps or spasms (e.g. diciclomina), for the treatment of Parkinson's disease (e.g. amantadina), or to prevent motion sickness (e.g. difenhidramina, escopolamina, or meclizina).

This medicationshould not be administered at the same time as metoclopramide (a medication used to relieve or prevent nausea and vomiting). Taking the two medications together may cause problems such as stiffness in the limbs and hand tremors.

If you need to undergo surgery while using this medication, inform your doctor that you are using it, as it may excessively potentiate the effects of some anesthetic muscle relaxants.

Care should be taken when using this medicationwith beta blockers (medications such as atenolol used to treat hypertension, angina, and other heart conditions). Taking the two medications together may cause complications such as a decrease in heart rate (bradycardia) that may lead to fainting or loss of consciousness.

Care should be taken when using Alzerta with other medications that may affect heart rhythm or the heart's electrical system (prolongation of QT).

Pregnancy, breastfeeding, and fertility

If you are pregnant or breastfeeding, or if you think you may be pregnant or plan to become pregnant, consult your doctor or pharmacist before using this medication.

If you are pregnant, it is necessary to evaluate the benefits of using this medication against the possible adverse effects on the fetus. This medication should not be used during pregnancy unless it is clearly necessary.

You should not breastfeed during your treatment with this medication.

Driving and operating machinery

Your doctor will inform you if your condition allows you to drive or use machinery safely. This medication may cause dizziness and severe confusion. If you feel dizzy or confused, do not drive, use machinery, or perform other tasks that require your attention.

3. How to use Alzerta

Follow exactly the administration instructions of this medication indicated by your doctor. In case of doubt, consult your doctor or pharmacist again.

How to start treatment

Your doctor will indicate the most suitable dose of this medication for your case.

  • Normally, treatment starts with Alzerta 4.6 mg/24 h.
  • The recommended daily dose is Alzerta 9.5 mg/24 h. If this dose is well tolerated, your doctor may consider increasing the dose to 13.3 mg/24 h.
  • Only wear one patch of this medication at a time and replace the patch with a new one every 24 hours.

Your doctor may adjust the dose during treatment depending on your individual needs.

If you have not used the patches for more than three days, do not apply a new one without consulting your doctor. Treatment with a transdermal patch can be restarted at the same dose if treatment is not interrupted for more than three days. Otherwise, your doctor will have you restart your treatment with Alzerta 4.6 mg/24 h.

This medication can be used with food, drink, and alcohol.

Where to place your Alzerta transdermal patch

  • Before applying a patch, ensure that the skin is clean, dry, and free of hair, powders, oils, moisturizers, or lotions that may prevent the patch from adhering well to the skin, without cuts, redness, or irritation.
  • Remove any existing patch carefully before applying a new one.This may expose you to an excessive amount of this medication, which could be potentially hazardous.
  • Apply only one patch per day in one of the possible areas as shown in the following diagrams:
  • upper left or right armorupper left or right chest (avoiding breasts in women)
  • upper left or right back
  • lower left or right back

Every 24 hours, remove the previous patch before applying a new one in only one of the possible areas.

During treatment, your doctor may adjust the dose depending on your individual needs.

Each time you change the patch, remove the previous patch before applying a new one in a different area of the skin (for example, one day on the right side of the body and the next day on the left side; or one day on the upper part of the body and the next day on the lower part). Wait at least 14 days before reapplying a patch to the same area of skin.

How to apply your Alzerta transdermal patch

Alzerta patches are thin, brown, and adhere to the skin. Each patch is found in a protective envelope that protects it until it is applied. Do not open the envelope or remove the patch until you are ready to apply it.

Remove the existing patch carefully before applying a new one.

Patients starting treatment for the first time and patients restarting treatment with rivastigmine after interrupting treatment should start with the second figure.

Each patch is found in an individual protective envelope.

Only open the envelope when you are ready to apply the patch.

Open the envelope by cutting along both scissors marks, but not beyond the indicated line. Do not cut the entire length of the envelope to avoid damaging the patch.

Remove the patch from the envelope.

Remove the top cover from the patch, on the beige side, and discard it. A protective layer covers the adhesive side of the patch. Remove the first layer of the protective layer without touching the adhesive side of the patch with your fingers.

Place the adhesive side of the patch on the upper or lower back or on the arm or chest and then remove the second layer of the protective layer.

Press the patch firmly against the skin with the palm of your hand for at least 30seconds and ensure that the edges have adhered well.

IMPORTANT:

  • Remove the previous patch before applying a new one.
  • Only one patch per day.
  • Do not cut the patch into pieces.
  • Press the patch firmly against the skin with the palm of your hand for at least 30 seconds.

You can write on the patch, for example, the day of the week, with a fine-tip red pen.

You must wear the patch continuously until you change it for a new one. When applying a new patch, you can try different areas to find the ones that are most comfortable and where clothing does not rub against the patch.

How to remove your Alzerta transdermal patch

Gently pull one of the edges of the patch to remove it slowly from the skin. If there are any remaining adhesive residues on the skin, soak the area with warm water and mild soap or use baby oil to remove it. Do not use alcohol or other solvents (nail polish removers or other solvents).

After removing the patch, wash your hands with soap and water. If you come into contact with your eyes or if your eyes become red after handling the patch, wash immediately with plenty of water and seek medical advice if the symptoms do not resolve.

Can you wear your Alzerta transdermal patch when bathing, swimming, or exposing yourself to the sun?

  • Bathing, swimming, or showering should not affect the patch. Ensure that it does not come loose during these activities.
  • Do not expose the patch to an external heat source (e.g., excessive sunlight, sauna, solarium) for extended periods.

What to do if a patch falls off

If a patch falls off, apply a new one for the rest of the day and change it the next day at the usual time.

How long and when should you wear your Alzerta transdermal patch?

  • To benefit from your treatment, you must apply a new patch every day, preferably at the same time.
  • Only wear one patch of this medication at a time and replace the patch with a new one every 24 hours.

If you use more Alzerta than you should

If you accidentally applied more than one patch, remove all patches from the skin and inform your doctor or call the Toxicological Information Service, phone: 91 562 04 20 (indicating the medication and the amount administered). You may need medical attention. Some people who have taken accidentally high amounts of rivastigmine have experienced nausea, vomiting, diarrhea, high blood pressure, and hallucinations.They may also experience a slowing of heart rate and dizziness.

If you forget to use Alzerta

If you realize you have forgotten to apply a patch, apply it immediately. The next day, apply the next patch at the usual time. Do not apply two patches to compensate for the one you forgot.

If you interrupt treatment with Alzerta

Inform your doctor or pharmacist if you stop using the patches.

If you have any other questions about the use of this medication, ask your doctor or pharmacist.

4. Possible Adverse Effects

Like all medications, Alzerta transdermal patches may cause side effects, although not everyone will experience them.

You may experience side effects more frequently when you start treatment or when your dose is increased. Generally, side effects will slowly disappear as your body gets used to the medication.

If you notice any of the following serious side effects, remove the patch and immediately inform your doctor.

Frequent(may affect up to 1 in 10 people)

  • Loss of appetite
  • Sensation of dizziness
  • Sensation of agitation or numbness
  • Urinary incontinence (inability to stop urinating properly).

Poorly frequent(may affect up to 1 in 100 people)

  • Problems with your heart rhythm, such as slow heart rate
  • Seeing things that do not exist (hallucinations)
  • Stomach ulcer
  • Dehydration (loss of a large amount of fluid)
  • Hyperactivity (high level of activity, restlessness)
  • Aggression

Rare(may affect up to 1 in 1,000 people)

  • Falls

Very rare(may affect up to 1 in 10,000 people)

  • Rigidity of arms and legs
  • Tremor in the hands

Unknown(cannot be estimated from available data)

  • Allergic reaction where the patch was applied, such as blisters or skin inflammation
  • Worsening of Parkinson's disease symptoms– such as tremor, rigidity, and difficulty moving
  • Syndrome of Pisa (condition involving involuntary muscle contraction and abnormal tilting of the body and head to one side)
  • Inflammation of the pancreas – symptoms include upper stomach pain, often accompanied by nausea or vomiting
  • Irregular heart rhythm or rapid heart rate
  • High blood pressure
  • Seizures (convulsions)
  • Liver disorders (yellowing of the skin, yellowing of the white of the eyes, abnormal darkening of the urine, or unexplained nausea, vomiting, fatigue, and loss of appetite)
  • Changes in liver function tests
  • Sensation of restlessness
  • Nightmares

If you notice any of the side effects listed above, remove the patch and immediately inform your doctor.

Other side effects experienced with rivastigmine capsules or oral solution and that may occur with patches:

Frequent(may affect up to 1 in 10 people)

  • Excessive salivation
  • Loss of appetite
  • Sensation of agitation
  • Sensation of general discomfort
  • Tremor or sensation of confusion
  • Increased sweating

Poorly frequent(may affect up to 1 in 100 people)

  • Irregular heart rhythm (e.g. rapid heart rate)
  • Difficulty sleeping
  • Accidental falls

Rare(may affect up to 1 in 1,000 people)

  • Seizures (convulsions)
  • Ulcer in the intestine
  • Chest pain– likely caused by a heart spasm

Very rare(may affect up to 1 in 10,000 people)

  • High blood pressure
  • Inflammation of the pancreas– symptoms include severe upper stomach pain, often accompanied by nausea or vomiting
  • Gastrointestinal bleeding – manifests as blood in the stool or vomiting blood
  • Seeing things that do not exist (hallucinations)
  • Some people who have experienced intense vomiting have had a tear in the esophagus, the tube that connects their mouth to their stomach

Reporting side effects

If you experience any type of side effect, consult your doctor or pharmacist, even ifit is a possible side effect that does not appear in this prospectus. You can also report them directly through the Spanish System for Pharmacovigilance of Medicines for Human Use, Website: www.notificaRAM.es.By reporting side effects, you can contribute to providing more information about the safety of this medication.

5. Alzerta Conservation

  • Keep this medication out of the sight and reach of children.
  • No use this medication after the expiration date that appears on the box and on the overwrap after CAD. The expiration date is the last day of the month indicated.
  • Store the transdermal patch inside the overwrap until use.
  • Do not use any patch if you observe that it is damaged or shows signs of manipulation.

After removing a patch, fold it in half with the adhesive side inward and press. After placing it in the original overwrap, dispose of the patch.Do not touch your eyes with your fingers and wash your hands with water and soap after removing the patch. If your household waste is disposed of by incineration, you may dispose of the patch in your household waste.

Medications should not be disposed of through drains or in the trash. Deposit the containers and medications you do not need at the SIGRE collection point at the pharmacy. In case of doubt, ask your pharmacist how to dispose of the containers and medications you do not need. This way, you will help protect the environment.

6. Content of the container and additional information

Composition of Alzerta

The active ingredient is rivastigmina.

Alzerta 4.6 mg/24 h transdermal patches EFG:

Each transdermal patch releases 4.6 mg of rivastigmina in 24 hours. Each transdermal patch of 4.6 cm2contains 6.9 mg of rivastigmina.

Alzerta 9.5 mg/24 h transdermal patches EFG:

Each transdermal patch releases 9.5 mg of rivastigmina in 24 hours. Each transdermal patch of 9.2 cm2contains 13.8 mg of rivastigmina.

The other components are coated polyester/aluminum/poly(2-ethylhexyl acrylate, vinyl acetate), polyisobutene of medium and high molecular weight, anhydrous colloidal silica, light liquid paraffin, coated polyester film with fluoropolymer, orange printing ink.

Appearance of the product and content of the container

Each transdermal patch is a thin, circular patch. The outer layer is a toasted color and carries the following orange printing:

  • “RIV-TDS 4.6 mg/24h”.
  • “RIV-TDS 9.5 mg/24h”.

Each transdermal patch is sealed in a sachet. Each transdermal patch is protected by a sheet. Alzerta 4.6 and 9.5 mg/24 h transdermal patches EFG, are available in containers containing 7, 30, or 42 sachets and in multiple containers containing 60 (2x30), 84 (2x42), or 90 (3x30) sachets.

Only some container sizes may be commercially available.

Marketing authorization holder and responsible manufacturer

Marketing authorization holder

Esteve Pharmaceuticals, S.A.

Passeig de la Zona Franca, 109

08038 Barcelona

Spain

Responsible manufacturer

Luye Pharma AG

Am Windfeld 35

83714 Miesbach

Germany

Last review date of this leaflet: December 2024

Detailed and updated information on this medicine is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS)http://www.aemps.gob.es/

Country of registration
Active substance
Prescription required
Yes
This information is for reference only and does not constitute medical advice. Always consult a licensed doctor before taking any medication. Oladoctor is not responsible for medical decisions based on this content.

Talk to a doctor online

Have questions about this medication or your symptoms? Connect with a licensed doctor for guidance and personalized care.

5.01 review
Doctor

Anna Moret

Dermatology18 years of experience

Dr. Anna Moret is a board-certified dermatologist and dermatovenereologist. She specialises in adult and pediatric dermatology, venereology, aesthetic skin care, and general medicine. Her consultations are evidence-based and tailored to each patient’s dermatological needs.

Dr. Moret provides expert evaluation and treatment for: • Skin conditions such as eczema, acne, rosacea, dermatitis, and psoriasis • Hair and scalp issues including hair loss, dandruff, and seborrheic dermatitis • Pediatric skin problems — from newborns to adolescents • Sexually transmitted infections (STIs) and dermatovenereology • Aesthetic concerns: skin ageing, non-invasive cosmetic treatments • Skin allergies and hypersensitivity reactions • Mole checks, lesion evaluation, and skin cancer screening • Skincare advice and personalised cosmeceutical routines

Combining dermatology with general medical knowledge, Dr. Moret offers comprehensive care that addresses both skin health and underlying conditions. She also holds certification from the Canadian Board of Aesthetic Medicine, ensuring an internationally aligned approach to aesthetic dermatology.

CameraBook a video appointment
5.05 reviews
Doctor

Alina Tsurkan

Family medicine12 years of experience

Dr. Alina Tsurkan is a licensed family medicine physician based in Portugal, offering online consultations for adults and children. She provides professional primary care, with a focus on prevention, accurate diagnosis, and long-term management of acute and chronic conditions.

Dr. Tsurkan supports patients with a wide range of health issues, including: • Respiratory infections: cold, flu, bronchitis, pneumonia, and lingering coughs • ENT conditions: sinusitis, tonsillitis, otitis (ear infections), sore throat, allergic rhinitis • Eye conditions: allergic or infectious conjunctivitis, red eyes, irritation • Digestive issues: acid reflux (GERD), gastritis, irritable bowel syndrome (IBS), constipation, bloating, nausea • Urinary and reproductive health: urinary tract infections (UTIs), cystitis, prevention of recurrent infections • Chronic diseases: hypertension, diabetes, thyroid disorders, elevated cholesterol, weight management • Neurological complaints: headaches, migraines, sleep disturbances, fatigue, general weakness • Women’s health: menstrual irregularities, perimenopausal symptoms, preventive screening • Children’s health: fever, infections, digestive issues, follow-ups, vaccination guidance

She also provides: • IMT medical certificates for driving licence exchange in Portugal • Personalised preventive care and wellness consultations • Interpretation of test results and medical reports • Follow-up care and medication review • Support in managing multiple coexisting conditions • Remote prescription management and medical documentation

Dr. Tsurkan’s approach is evidence-based and holistic. She works closely with each patient to develop an individualised care plan that addresses both symptoms and root causes. Her goal is to empower patients to take control of their health and maintain well-being through lifestyle adjustments, routine check-ups, and early intervention.

CameraBook a video appointment
5.04 reviews
Doctor

Andrei Popov

General medicine6 years of experience

Dr. Andrei Popov is a licensed pain management specialist and general practitioner based in Spain. He provides expert online care for adults dealing with both chronic and acute pain, as well as a wide range of everyday health concerns.

He specialises in diagnosing and treating pain conditions that affect quality of life, including: • Chronic pain lasting more than 3 months • Migraines and recurring headaches • Neck, back, lower back, and joint pain • Post-traumatic pain following injury or surgery • Nerve-related pain, fibromyalgia, and neuralgia In addition to pain management, Dr. Popov helps patients with: • Respiratory infections (colds, bronchitis, pneumonia) • High blood pressure and metabolic conditions such as diabetes • Preventive care and routine health check-ups

Online consultations last up to 30 minutes and include a detailed symptom review, personalised treatment planning, and medical follow-up when needed.

Dr. Popov’s approach is rooted in evidence-based medicine, combined with individualised care tailored to each patient’s history, lifestyle, and clinical needs.

CameraBook a video appointment
5.03 reviews
Doctor

Yevgen Yakovenko

General surgery11 years of experience

Dr. Yevhenii Yakovenko is a licensed surgeon and general practitioner in Spain and Germany. He specialises in general, paediatric, and oncological surgery, internal medicine, and pain management. He offers online consultations for adults and children, combining surgical precision with therapeutic support. Dr Yakovenko works with patients across different countries and provides care in Ukrainian, Russian, English, and Spanish.

Areas of medical expertise: • Acute and chronic pain: headaches, muscle and joint pain, back pain, abdominal pain, postoperative pain. Identifying the cause, selecting treatment, and creating a care plan. • Internal medicine: heart, lungs, gastrointestinal tract, urinary system. Management of chronic conditions, symptom control, second opinions. • Pre- and postoperative care: risk assessment, decision-making support, follow-up after surgery, rehabilitation strategies. • General and paediatric surgery: hernias, appendicitis, congenital conditions, both planned and urgent surgeries. • Injuries and trauma: bruises, fractures, sprains, soft tissue damage, wound care, dressing, referral when in-person care is required. • Oncological surgery: diagnosis review, treatment planning, and long-term follow-up. • Imaging interpretation: analysis of ultrasound, CT, MRI, and X-ray results, surgical planning based on imaging data. • Second opinions and medical navigation: clarifying diagnoses, reviewing current treatment plans, helping patients choose the best course of action.

Experience and qualifications: • 12+ years of clinical experience in university hospitals in Germany and Spain • International education: Ukraine – Germany – Spain • Member of the German Society of Surgeons (BDC) • Certified in radiological diagnostics and robotic surgery • Active participant in international medical conferences and research

Dr Yakovenko explains complex topics in a clear, accessible way. He works collaboratively with patients to analyse health issues and make evidence-based decisions. His approach is grounded in clinical excellence, scientific accuracy, and respect for each individual.

If you are unsure about a diagnosis, preparing for surgery, or want to discuss your test results – Dr Yakovenko will help you evaluate your options and move forward with confidence.

CameraBook a video appointment
See all doctors

Stay informed and save on care

Get health tips, platform updates, and exclusive promos for subscribers.

Follow us on social media
FacebookInstagramTikTok